Abbott Laboratories (ABT.N)
36.84USD
4:01pm EDT
$0.21 (+0.57%)
$36.63
$36.89
$37.07
$36.68
1,985,682
1,999,563
$72.47
$31.65
About
Overall
| Beta: | 0.36 |
| Market Cap (Mil.): | $57,101.21 |
| Shares Outstanding (Mil.): | 1,558.86 |
| Dividend: | 0.14 |
| Yield (%): | 1.53 |
Financials
| ABT.N | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 69.17 | 37.93 | 37.76 |
| EPS (TTM): | 0.53 | -- | -- |
| ROI: | -- | 19.48 | 18.76 |
| ROE: | -- | 20.17 | 19.59 |
Abbott profit beats forecast, nutritional products strong
- Abbott Laboratories reported better-than-expected second-quarter earnings on Wednesday as strong demand for nutritional products offset lower sales of medical devices and generic prescription drugs.
UPDATE 3-Abbott profit beats forecast, nutritional products strong
* Adj earnings 46 cents/share vs Wall Street view 44 cents
Abbott profit beats forecast, nutrition brands offset weak device sales
July 17 - Abbott Laboratories reported better-than-expected quarterly earnings on Wednesday as strong demand for its nutritional products offset lower sales of medical devices and generic prescription drugs.
Abbott to cut milk powder prices in China after probe
SHANGHAI, July 12 - Abbott Laboratories is cutting prices of its instant products in China by up to 12 percent, the company said, joining other foreign firms in responding to Beijing's probe into possible price-fixing by milk powder makers.
UPDATE 2-China probes infant milk firms for antitrust violations
* Danone, Nestle, Mead Johnson, Abbott cooperating with investigation
Abbvie says Chief Scientific Officer John Leonard to retire
- AbbVie Inc's chief scientific officer will be retiring in the next few months and will be involved in the process of naming a successor, the pharmaceutical company said in a regulatory filing on Friday.
Abbvie says Chief Scientific Officer John Leonard to retire
May 10 - AbbVie Inc's chief scientific officer will be retiring in the next few months and will be involved in the process of naming a successor, the pharmaceutical company said in a regulatory filing on Friday.
UPDATE 1-Russia rejects Abbott Laboratories' plan to buy Petrovax
MOSCOW, April 19 - Russia's government commission on foreign investment has turned down U.S. group Abbott Laboratories' request to buy Russian vaccine maker Petrovax, the head of Russia's competition regulator said on Friday.
Russia rejects Abbott Laboratories' plan to buy Petrovax
MOSCOW - Russia's government commission on foreign investment has rejected U.S. Abbott Laboratories' plan to buy Russian pharmaceutical producer Petrovax, the head of the Russian antitrust regulator said on Friday.
Russia rejects Abbott Laboratories' plan to buy Petrovax
MOSCOW, April 19 - Russia's government commission on foreign investment has rejected U.S. Abbott Laboratories' plan to buy Russian pharmaceutical producer Petrovax, the head of the Russian antitrust regulator said on Friday.
Competitors
| Price | Change | |
|---|---|---|
| Johnson & Johnson (JNJ.N) | $93.77 | +0.27 |
| Pfizer Inc. (PFE.N) | $29.11 | -0.12 |
| GlaxoSmithKline plc (GSK.L) | 1,712.50p | +28.50 |
| Novartis AG (NOVN.VX) | CHF66.60 | +0.35 |
| Eli Lilly & Co. (LLY.N) | $53.50 | +0.39 |
| Merck & Co., Inc. (MRK.N) | $48.58 | +0.41 |
| AstraZeneca plc (AZN.L) | 3,334.00p | -1.00 |
| Sanofi SA (SASY.PA) | €76.85 | -3.32 |
| Amgen, Inc. (AMGN.OQ) | $109.45 | +1.16 |
| Angiotech Pharmaceuticals, Inc. (USA) (ANPMF.PK) | $25.00 | +8.25 |
Earnings vs.
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: ValuEngine, Inc.
|
$25.00
|
|
Provider: ValuEngine, Inc.
|
$25.00
|
|
Provider: Wright Reports
|
$472.00
|
|
Trading Report for (ABT). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
|
$58.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

